Hsbc Holdings PLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Hsbc Holdings PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $35,077 - $36,854	-242 Reduced 0.27%	88,657 $13.4 Million
Q2 2022 Aug 11, 2022	BUY	$83.14 - $145.99 $7.01 Million - $12.3 Million	84,342 Added 1850.82%	88,899 $12.9 Million
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $250,762 - $325,571	-2,278 Reduced 33.33%	4,557 $545,000
Q4 2021 Feb 11, 2022	BUY	$99.73 - $148.48 $343,270 - $511,068	3,442 Added 101.44%	6,835 $941,000
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $40,825 - $57,369	-413 Reduced 10.85%	3,393 $456,000
Q2 2021 Aug 13, 2021	BUY	$65.78 - $105.02 $250,358 - $399,706	3,806 New	3,806 $369,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.